84
Participants
Start Date
January 8, 2020
Primary Completion Date
September 2, 2021
Study Completion Date
September 2, 2021
BW-1010: 50 µg - sprayer - IN
"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
BW-1010: 50 µg - pipette - IN
"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
BW-1010: 100 µg - sprayer - IN
"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart"
BW-1010: 100 µg - pipette - IN
"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
Saline (Placebo) - sprayer - IN
"Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
Saline (Placebo) - pipette - IN
"Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
BioThrax (positive control) - SC
"BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart."
Johnson County Clin-Trial, Lenexa
Lead Sponsor
Collaborators (1)
Porton Biopharma Ltd.
UNKNOWN
BlueWillow Biologics
INDUSTRY